The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study-Reference-Cited by-同舟云学术

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study

Published:2019-05-01 Issue:1 Volume:81 Page:e17-e21
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Rossetti Barbara,Gagliardini Roberta,Sterrantino Gaetana,Colangeli Vincenzo,Latini Alessandra,Colafigli Manuela,Vignale Francesca,Rusconi Stefano,Di Biagio Antonio,Orofino Giancarlo,Mezzaroma Ivano,Vullo Vincenzo,Francisci Daniela,Mastroianni Claudio,Trezzi Michele,Canovari Benedetta,Lamonica Silvia,Ciccullo Arturo,Borghetti Alberto,D'Arminio Monforte Antonella,Di Giambenedetto Simona,De Luca Andrea,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference10 articles.

1. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model;Ochoa-Callejero;PLoS One.,2013

2. Preface;Friedman;Clin Liver Dis.,2008

3. CCR1 and CCR5 promote hepatic fibrosis in mice;Seki;J Clin Invest.,2009

4. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice;Berres;J Clin Invest.,2010

5. Gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis;Bruno;Gut.,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?;Cells;2021-05-15